India on Friday reported 6,168 new Covid cases and 21 deaths in the last 24 hours, as per the Union Health Ministry data.
The death toll currently stands at 5,27,932, says the report.
Meanwhile, the active caseload has come down to 59,210 cases, accounting for 0.13 per cent of the total positive cases.
The recovery of 9,685 patients in the last 24 hours took the cumulative tally to 4,38,55,365. Consequently, the recovery rate stands at 98.68 per cent.
Meanwhile, the Positivity rate has marginally declined to 1.94 per cent, while the Weekly Positivity Rate in the country stands at 2.51 per cent.
Also in the same period, a total of 3,18,642 tests were conducted, increasing the overall tally to over 88.64 crore.
As of this morning, the Covid-19 vaccination coverage exceeded 212.75 crore.
Over 4.03 crore adolescents have been administered with a first dose of Covid-19 jab since the
Maharashtra today reported 1,258 new COVID-19 cases and six more deaths linked to the infection, which took the tally to 81,02,377 and the toll to 1,48,257, a health official said. Of the new cases, 678 were from the Mumbai administrative circle, followed by the Pune (381), Nagpur (56), Kolhapur (49), Nashik (35), Akola (16), Aurangabad (12) and the Latur circle (9).
Coronavirus figures of Maharashtra are as follows: Positive cases 81,02,377; fresh cases 1,258; death toll 1,48,257; recoveries 79,44,923; active cases 9,197; total tests 8,41,62,354
Telangana on Friday recorded 177 new COVID-19 cases, taking the tally to 8,34,814. Hyderabad district saw most of the cases with 69. A health department bulletin said 290 people recuperated from the infection and the cumulative number of recoveries was 8,29,410 till date.
Orissa’s COVID-19 tally rose to 13,28,070 on Friday as 226 more people, including 19 children, tested positive for the infection, a health bulletin said.
The toll rose to 9,178 as an 81-year-old man succumbed to the disease in Bhubaneswar. Fifty-three other patients have died due to comorbidities so far, it said.
The state has 1,797 active cases, while 228 more people recovered in the last 24 hours, taking the total recoveries to 13,17,042. The positivity rate was at 1.74 per cent as the new cases were detected after testing 13,026 samples.
Delhi on Friday reported 299 new Covid cases in the last 24 hours, against 271 on previous day, and two more deaths, the Delhi health bulletin said.
Meanwhile, the Covid positivity rate of the city stands 2.17 per cent. The number of active cases stands at 1,457 out of which 996 patients are being treated in home isolation.
With 461 patients recovering in the last 24 hours, the total number of recoveries has gone to 19,72,256, while Delhi’s total caseload is 20,00,187 and the death toll in the city has risen to 26,475.
The number of Covid containment zones stands at 159.
A total of 13,772 new tests — 8,778 RT-PCR and 4,994 Rapid Antigen – were conducted in the last 24 hours, taking the total to 3,99,74,243 while 27,936 vaccines were administered – 1,662 first doses, 4,245 second doses, and 22,029 precaution doses.
The total number of cumulative beneficiaries vaccinated so far stands at 3,65,94,221, according to the health bulletin.
Meanwhile, The European Medicines Agency (EMA) on Thursday backed the use of Novavax’s COVID-19 shot as a booster for adults, ahead of an anticipated rise in infections this winter.
The vaccine, Nuvaxovid, is designed to target the strain of the virus that originally emerged in China. The EMA’s recommendation is for people who previously were inoculated with either the Novavax shot, or any other COVID vaccine.
Separately on Thursday, the EMA backed two separate COVID-19 vaccine boosters updated to target the Omicron variant of the virus.
Developed by Moderna and the team of Pfizer and BioNTech, the new so-called bivalent shots combat the BA.1 version of Omicron and the original virus first detected in China.
Novavax’s Nuvaxovid made its debut well after first set of COVID-19 shots – including those from Moderna, Pfizer-BioNTech, AstraZeneca and Johnson & Johnson – were approved in different parts of the world.
The hope was Nuvaxovid would incentivise people who were sceptical of some shots based on the newer mRNA technology to get vaccinated, given Nuvaxovid relies on technology that has been used for decades to combat diseases including hepatitis B and influenza.
However, demand has been tepid. Last month, the U.S. vaccine maker Novavax cut its annual revenue forecast by half, on limited demand for its shot as a primary course.
Read more Health News
